AMAL develops peptide/protein-based therapeutic vaccines based on a proprietary technology platform called KISIMA®
Licensing opportunities
The KISIMA® technology is highly versatile and flexible with potential applications including therapeutic vaccines in oncology, but also in infectious diseases. KISIMA® can also be developed as a synthetic platform for the delivery of neo-antigens or modified epitopes.
Our strategy is to develop KISIMA® and its current indications in oncology (including metastatic colorectal cancer) through to phase II, in-house or through strategic partnerships.
ATP128, our first asset is anticipated to start phase I clinical trial in 2019. We would then consider out licensing it to advance our other undisclosed assets as well as explore additional indications.
Ongoing collaborations
We have signed an exclusive patent license agreement with the University of Minnesota and the University of Geneva for different components of KISIMA®.
We also have a research collaboration agreement with the University of Tübingen and ongoing collaborations with academic groups and KOLs to further explore the potential of our KISIMA® platform, including the Geneva University, the HUG (Hopitaux Universitaires de Genève), the Fox Chase Cancer Center, the MD Anderson Cancer Center, and the University Hospital Padova (Italy).
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
